Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer.

Background: The addition of bevacizumab to standard chemotherapy has significant clinical benefits in metastatic colorectal cancer. However, its use is often avoided due to patient condition or disease status.

Methods: Of 228 consecutive patients receiving first-line FOLFOX-based regimens from June 2007 to June 2009, 96 patients (42 %) received FOLFOX alone without bevacizumab.

Control on shape, porosity and surface hydrophilicity of hematite particles by using polymers.

The shape, porosity, and surface hydrophilicity of hematite particles formed from a forced hydrolysis reaction of acidic FeCl solution were controlled by using a trace of polymers (0.001 and 0.003 wt%).